ES2139017T3 - Compuestos que inhiben la replicacion del vih. - Google Patents

Compuestos que inhiben la replicacion del vih.

Info

Publication number
ES2139017T3
ES2139017T3 ES93917272T ES93917272T ES2139017T3 ES 2139017 T3 ES2139017 T3 ES 2139017T3 ES 93917272 T ES93917272 T ES 93917272T ES 93917272 T ES93917272 T ES 93917272T ES 2139017 T3 ES2139017 T3 ES 2139017T3
Authority
ES
Spain
Prior art keywords
hiv
refers
hiv replication
inhibiting hiv
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917272T
Other languages
English (en)
Inventor
Carl T Wild
Thomas J Matthews
Dani P Bolognesi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Application granted granted Critical
Publication of ES2139017T3 publication Critical patent/ES2139017T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A FRAGMENTOS DE PROTEINAS DEL VIRUS DE INMUNODEFICIENCIA HUMANA (VIH) QUE POSEEN UNA ACTIVIDAD ANTIVIRAL Y EN PARTICULAR SE REFIERE A PEPTIDOS DEL VIH DERIVADOS DE LA GLICOPROTEINA DE LA TRANSMEMBRANA DEL VIH (GP41) QUE INHIBE LA FUSION CELULA-CELULA INDUCIDA POR EL VIH. LA INVENCION TAMBIEN SE REFIERE A LOS METODOS PARA INHIBIR LA INFECCION DE VIRUS CON TUNICA Y A METODOS QUE MODULAN LOS PROCESOS BIOQUIMICOS EN LOS QUE INTERVIENEN INTERACCIONES DE PEPTIDOS RIZADOS EN ESPIRAL.
ES93917272T 1992-07-20 1993-07-19 Compuestos que inhiben la replicacion del vih. Expired - Lifetime ES2139017T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91654092A 1992-07-20 1992-07-20
US92753292A 1992-08-07 1992-08-07

Publications (1)

Publication Number Publication Date
ES2139017T3 true ES2139017T3 (es) 2000-02-01

Family

ID=27129697

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917272T Expired - Lifetime ES2139017T3 (es) 1992-07-20 1993-07-19 Compuestos que inhiben la replicacion del vih.

Country Status (11)

Country Link
US (3) US5656480A (es)
EP (1) EP0652895B1 (es)
JP (1) JP4010560B2 (es)
KR (1) KR100358209B1 (es)
AT (1) ATE183515T1 (es)
AU (1) AU688733B2 (es)
CA (1) CA2140663C (es)
DE (1) DE69326069T2 (es)
ES (1) ES2139017T3 (es)
NZ (1) NZ254640A (es)
WO (1) WO1994002505A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100358209B1 (ko) * 1992-07-20 2003-01-24 듀크 유니버시티 Hiv복제를저해하는조성물
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
EP0831873A4 (en) * 1995-06-07 2002-07-17 Trimeris Inc COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US6303317B1 (en) 1997-01-28 2001-10-16 The Regents Of The University Of California Peptide probes and methods for making the same
US6150088A (en) 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
WO2000006599A1 (en) * 1998-07-30 2000-02-10 Whitehead Institute For Biomedical Research Inhibitors of hiv membrane fusion
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
GB9801070D0 (en) * 1998-01-19 1998-03-18 Andaris Ltd HIV inhibition
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6747126B1 (en) 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
US7960504B2 (en) 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
AU2604200A (en) * 1999-01-08 2000-07-24 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
CA2372338A1 (en) * 1999-05-17 2000-11-23 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
ES2296665T3 (es) 1999-12-16 2008-05-01 Whitehead Institute For Biomedical Research Proteina cinco-helice.
US20030082525A1 (en) * 1999-12-16 2003-05-01 Whitehead Institute For Biomedical Research Five-Helix protein
NZ520754A (en) 2000-02-10 2004-02-27 Panacos Pharmaceuticals Inc Identifying compounds that disrupt formation of critical gp41 six-helix bundle and conformations necessary for HIV entry thereby blocking virus entry to the cell
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
US6528308B1 (en) 2000-03-16 2003-03-04 Duke University Suppressor of HIV replication and transcription
AU2001243639A1 (en) * 2000-03-17 2001-10-03 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
DE60216151T2 (de) * 2001-05-31 2007-09-27 ConjuChem Biotechnologies Inc., Montreal Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
EP1752469B1 (en) * 2001-05-31 2008-10-29 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors for HIV infection
CN1255548C (zh) 2001-06-15 2006-05-10 霍夫曼-拉罗奇有限公司 gp41片段的乙酰化
WO2003006056A2 (en) * 2001-07-11 2003-01-23 Genfa Zhou End-locked five-helix protein
CN1100564C (zh) * 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
AU2002351176A1 (en) * 2001-11-29 2003-06-17 Mymetics, Corp. Peptides and use thereof in therapeutic agents against hiv infection
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
US20040076637A1 (en) * 2002-09-27 2004-04-22 Delmedico Mary Kay HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
WO2004035808A2 (en) * 2002-10-16 2004-04-29 Panacos Pharmaceuticals, Inc. Method for detecting viral inactivating agents
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US20060104988A1 (en) * 2002-12-18 2006-05-18 Pauza C D Vaccines against hiv-1 tat protein to generate neutralizing antibodies
CN1829524A (zh) * 2003-05-08 2006-09-06 波特·W·安德森 基于gp160和人cd4蛋白共有的保守氨基酸序列的抗hiv－1化合物
AU2003265420A1 (en) * 2003-08-14 2005-03-10 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Polypeptide multimers having antiviral activity
KR20050024730A (ko) * 2003-09-01 2005-03-11 코바이오텍 (주) Ｔ―２０ 펩타이드 코딩 유전자를 포함하는 재조합대장균의 고농도 세포 배양 방법 및 이로부터 생산된ｔ―２０ 펩타이드의 분리 및 정제 방법
AU2004308952A1 (en) 2003-12-23 2005-07-14 Centocor, Inc. Anti-retroviral agents, compositions, methods and uses
ATE410437T1 (de) * 2003-12-31 2008-10-15 Hoffmann La Roche Verfahren und systeme zur rückgewinnung von peptiden
EP1701971A2 (en) * 2003-12-31 2006-09-20 F.Hoffmann-La Roche Ag Peptide synthesis using decanting filter
DE602004009710T2 (de) * 2003-12-31 2008-08-07 F. Hoffmann-La Roche Ag Verfahren zur peptidsynthese unter verwendung einer reduzierten menge an entschützungsmittel
WO2005063799A2 (en) * 2003-12-31 2005-07-14 F.Hoffmann-La Roche Ag Peptide synthesis and deprotection with co-solvent
EP1701970A2 (en) * 2003-12-31 2006-09-20 F.Hoffmann-La Roche Ag Methods for recovering cleaved peptide from a support
RU2006128593A (ru) * 2004-01-07 2008-02-20 Тримерис, Инк. (Us) Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека
EP1747233A4 (en) * 2004-05-06 2007-04-25 COMPOUNDS FOR SPECIFIC VIRAL TARGET
ATE516048T1 (de) * 2004-06-01 2011-07-15 Merck Sharp & Dohme Mit hiv gp41 in wechselwirkung stehende menschliche antikörper
JP5069558B2 (ja) 2004-06-01 2012-11-07 メルク・シャープ・エンド・ドーム・コーポレイション ＨＩＶｇｐ４１融合中間物質の安定したペプチド模倣薬
WO2006069697A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Colorimetrically assessing peptide characteristics
ATE439371T1 (de) * 2004-12-30 2009-08-15 Hoffmann La Roche Synthese von peptid t-1249 mit peptidzwischenproduktfragmenten
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
ES2332418T3 (es) * 2004-12-30 2010-02-04 F. Hoffmann-La Roche Ag Sintesis del peptido t-20 empleando fragmentos intermedios del peptido.
WO2006105993A2 (en) * 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
EP1989220B1 (en) 2006-02-02 2011-12-14 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
JP2008005838A (ja) * 2006-05-31 2008-01-17 Wataru Sakamoto 新規ペルオキシダーゼ検出用試薬組成物及びこれを用いた炎症疾患等の判定法および抗酸化活性測定法
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
KR101105610B1 (ko) 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 Ｃｃｒ５ 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트
JP5492563B2 (ja) 2006-12-12 2014-05-14 バイオレクシス ファーマシューティカル コーポレーション トランスフェリン融合タンパク質ライブラリー
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CL2008000707A1 (es) * 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
KR20100016142A (ko) * 2007-04-03 2010-02-12 트라이머리스, 인코퍼레이티드 항바이러스 펩티드 치료제 전달용 신규 제제
US20090088377A1 (en) * 2007-05-16 2009-04-02 Conjuchem Biotechnologies, Inc. Cysteic acid derivatives of anti-viral peptides
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
KR20100080812A (ko) * 2007-09-25 2010-07-12 트라이머리스, 인코퍼레이티드 치료용 항-ｈｉｖ 펩티드의 합성 방법
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
EP2616487B1 (en) 2010-09-14 2015-03-25 F.Hoffmann-La Roche Ag Serpin-finger fusion polypeptide
WO2013150532A1 (en) 2012-04-04 2013-10-10 Yeda Research And Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8305985D0 (en) * 1983-03-04 1983-04-07 Szelke M Enzyme inhibition
AU7234387A (en) * 1986-03-24 1987-10-20 Ortho Pharmaceutical Corporation Synthetic htlv-iii peptides, compositions and uses thereof
US5030449A (en) * 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
EP0323157A3 (en) * 1987-12-24 1990-07-25 The University Of Melbourne Antiviral compounds and methods
EP0323425B1 (en) * 1987-12-28 1995-09-06 Yamaha Corporation An ivory-like key material and a method for producing the same
GB8828097D0 (en) * 1988-12-01 1989-01-05 Wellcome Found Peptides
US5444044A (en) * 1992-03-26 1995-08-22 New York Blood Center Synthetic polypeptides as inhibitors of HIV-1
KR100358209B1 (ko) * 1992-07-20 2003-01-24 듀크 유니버시티 Hiv복제를저해하는조성물
WO1994016109A1 (en) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same

Also Published As

Publication number Publication date
ATE183515T1 (de) 1999-09-15
DE69326069D1 (de) 1999-09-23
JP4010560B2 (ja) 2007-11-21
EP0652895B1 (en) 1999-08-18
US20030181382A1 (en) 2003-09-25
EP0652895A4 (en) 1997-02-05
CA2140663C (en) 2004-01-27
AU688733B2 (en) 1998-03-19
CA2140663A1 (en) 1994-02-03
JPH08500342A (ja) 1996-01-16
US6573078B1 (en) 2003-06-03
EP0652895A1 (en) 1995-05-17
AU4683793A (en) 1994-02-14
US5656480A (en) 1997-08-12
KR950702575A (ko) 1995-07-29
WO1994002505A1 (en) 1994-02-03
KR100358209B1 (ko) 2003-01-24
NZ254640A (en) 1997-04-24
DE69326069T2 (de) 2000-03-23

Similar Documents

Publication Publication Date Title
ES2139017T3 (es) Compuestos que inhiben la replicacion del vih.
ES2053413T3 (es) Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
ES2058199T3 (es) Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
MX9304837A (es) Peptidos capaces de inhibir la actividad de proteasa vih, su preparacion y su uso terapeutico.
MX9203379A (es) Proteinas producidas por los linfocitos humanos, secuencia de adn que codifica para estas proteinas y composiciones farmaceuticas que las contienen.
ES2078907T3 (es) Metodo para radiomarcar proteinas.
ES2002490A6 (es) Un metodo de preparar un virus recombinante
ES2087156T3 (es) Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.
ES2067457T3 (es) Celula de origen animal con una proteina antigenica introducida en ella.
PE43298A1 (es) Genes sinteticos de vih
ES2057191T3 (es) Metodo de produccion para una composicion que contiene proteinas.
ES2138086T3 (es) Constructo de peptido sintetico compuesto que provoca anticuerpos neutralizantes y linfocitos t citotoxicos contra hiv.
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
ES2115756T3 (es) Derivados de acido sulfonico utilizados en el tratamiento de enfermedades virales.
ES2066887T3 (es) Anticuerpo monoclonal para diferenciar individuos seropositivos hiv-2 de los hiv-1.
ATE54826T1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
ES2173923T3 (es) Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente.
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
ES2138603T3 (es) Procedimiento para el aislamiento de los factores ix, x y ii altamente purificados a partir del complejo protrombinico o del plasma humano.
MX9308005A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
ATE134195T1 (de) Peptidfragmente von hiv
ES2119747T3 (es) Metodo para la preparacion y purificacion de una mezcla de glicosfingolipidos libre de contaminacion por virus no convencionales.
ES2118242T3 (es) Vacunas anti virus de la inmunodeficiencia felina (fiv).
ES2054769T3 (es) Polipeptidos hiv-2 recombinantes.
ES2044976T3 (es) Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652895

Country of ref document: ES